# Neurocrine Biosciences

> Neurocrine Biosciences is a San Diego biopharmaceutical company that discovers, develops and commercializes medicines for under-addressed neurological, psychiatric, endocrine and immunological disorders. Its business is anchored by INGREZZA, a VMAT2 inhibitor for tardive dyskinesia and Huntington's disease chorea, and has expanded through CRENESSITY for classic congenital adrenal hyperplasia and the 2026 acquisition of VYKAT XR for hyperphagia in Prader-Willi syndrome. With more than 2,000 employees, $2.86 billion in 2025 revenue and a broad clinical pipeline, Neurocrine sits between specialist biotech and a scaled commercial pharmaceutical company.

- **Founded:** 1992
- **Headquarters:** San Diego, United States
- **Founders:** Wylie Vale, Ph.D. (Co-founder), Lawrence Steinman, M.D. (Co-founder)
- **Team size:** More than 2,000 employees; LinkedIn lists 1,001-5,000 and the Los Angeles Times reported 2,009 company-wide in 2026.
- **Products:** INGREZZA (valbenazine), INGREZZA SPRINKLE (valbenazine), CRENESSITY (crinecerfont), VYKAT XR (diazoxide choline), ORILISSA and ORIAHNN collaboration
- **Notable:** FDA approval of INGREZZA in 2017 as the first treatment approved in the U.S. specifically for adults with tardive dyskinesia., FDA expansion of INGREZZA in 2023 to treat chorea associated with Huntington's disease., FDA approval of CRENESSITY in December 2024, the first new treatment approach for classic CAH in decades.

## Products & services

- **INGREZZA (valbenazine)** — A VMAT2 inhibitor approved in the U.S. for adults with tardive dyskinesia and for chorea associated with Huntington's disease.
- **INGREZZA SPRINKLE (valbenazine)** — An oral granules formulation that can be opened and sprinkled on soft food for eligible patients with tardive dyskinesia or Huntington's disease chorea.
- **CRENESSITY (crinecerfont)** — A CRF1 receptor antagonist used with glucocorticoids to control androgen levels in adults and children age four and older with classic congenital adrenal hyperplasia.
- **VYKAT XR (diazoxide choline)** — An extended-release treatment for hyperphagia in adults and children age four and older with Prader-Willi syndrome, added through the Soleno acquisition.
- **ORILISSA and ORIAHNN collaboration** — Elagolix-containing medicines commercialized by AbbVie for endometriosis and uterine fibroids; Neurocrine receives tiered royalties.
- **Clinical development pipeline** — Programs across psychiatry, neurology, endocrinology and immunology, including Phase 3 direclidine in schizophrenia and Phase 3 osavampator in major depressive disorder.
- **Patient access and support** — Product access, reimbursement navigation and patient-support services associated with its marketed U.S. medicines.

## Achievements

- FDA approval of INGREZZA in 2017 as the first treatment approved in the U.S. specifically for adults with tardive dyskinesia.
- FDA expansion of INGREZZA in 2023 to treat chorea associated with Huntington's disease.
- FDA approval of CRENESSITY in December 2024, the first new treatment approach for classic CAH in decades.
- Growth of INGREZZA net product sales to $2.51 billion in 2025.
- Total 2025 revenue of $2.86 billion, up from $2.36 billion in 2024.
- Completion of the $2.9 billion Soleno Therapeutics acquisition in May 2026, adding VYKAT XR.
- Second-quarter 2026 revenue of $959 million, up 39% year over year.
- Expansion from two founders to more than 2,000 employees and a broad mid-to-late-stage pipeline.

## Latest updates

- **2026-07** — Reported second-quarter revenue of $959 million, a 39% year-over-year increase.
- **2026-07** — Initiated a Phase 2 study of crinecerfont in children from 3 months to under 4 years old with classic CAH.
- **2026-07** — Appointed Samir Siddhanti chief business officer and announced additional leadership changes.
- **2026-05** — Completed the $2.9 billion acquisition of Soleno Therapeutics and added VYKAT XR to its commercial portfolio.
- **2026-05** — Reported first-quarter revenue of $814.5 million and initiated Phase 2 development of dual M1/M4 agonist NBI-1117570 in schizophrenia.
- **2026-04** — Announced the agreement to acquire Soleno Therapeutics for $53 per share in cash.

## Links

- Website: https://www.neurocrine.com/
- LinkedIn: https://www.linkedin.com/company/neurocrine/
- Twitter/X: https://x.com/neurocrine
- YouTube: https://www.youtube.com/@NeurocrineBiosciencesInc
- Facebook: https://www.facebook.com/Neurocrine/

---

Profile page: https://yespress.io/neurocrine-biosciences
Published by YesPress — https://yespress.io
Last updated: 2026-08-11